How much better are dual and triple incretin drugs than the older GLP-1 drugs?
The newer dual and triple agonists are significantly more effective than the first-generation GLP-1 drugs, especially for weight loss. While standard GLP-1 receptor agonists (like semaglutide) can reduce body weight by 5% to 22%, the dual GIP/GLP-1 agonist tirzepatide and the triple agonist retatrutide have pushed that ceiling much higher, achieving up to 24% body weight reduction in clinical trials [1][2]. This level of weight loss is comparable to what is typically seen after bariatric surgery, marking a major leap in non-surgical treatment [7].
For blood sugar control, the improvement is also substantial. GLP-1 drugs consistently lower HbA1c (a key measure of blood sugar over time) by 1% to 2% [1]. The dual and triple agonists build on this, providing superior glycemic control compared to selective GLP-1RAs alone, as seen with tirzepatide in head-to-head trials [5]. This means that for patients with type 2 diabetes, these newer drugs can bring blood sugar levels into a healthier range more effectively than older options.
Do these drugs do more than just help with weight and blood sugar?
Yes, the evidence points to benefits that go well beyond weight and glucose control, particularly for the heart, liver, and kidneys. The incretin hormones (GLP-1 and GIP) act as a critical link between digestion, metabolism, and cardiovascular function [3]. Clinical data shows that GLP-1-based therapies reduce the risk of major cardiovascular events (like heart attack or stroke) by 9% to 20% [1]. These drugs improve endothelial function (the lining of blood vessels), lower blood pressure, and have anti-inflammatory effects, which together help protect the heart and vessels [3][5].
For the liver, these drugs are emerging as a promising treatment for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease. Successful phase 2 clinical trials have shown that dual and triple agonists can improve liver inflammation and fibrosis, with several agents now moving into phase 3 trials [6][8]. This is a major development because there are currently very few effective drug treatments for MASH. The drugs appear to work both indirectly (through weight loss and improved insulin resistance) and potentially through direct effects on the liver [6].
Furthermore, the FDA has already approved tirzepatide for treating obstructive sleep apnea, a common and serious complication of obesity [10]. This illustrates how these drugs are being recognized for their broad effects on obesity-related comorbidities, shifting the focus of treatment from just managing blood sugar to protecting multiple organ systems [9].
What are the main catches or limitations?
Despite their promise, these drugs come with significant limitations that will shape their impact over the next decade. The most immediate issues are cost and tolerability. These are expensive medications, and major clinical trials have underrepresented people from low- and middle-income countries, raising concerns about equitable global access [2]. Side effects, particularly gastrointestinal issues like nausea and vomiting, are common and can lead to people stopping the medication [1][6].
Long-term safety is another major unknown. While the drugs have shown good safety profiles in trials lasting a few years, we do not yet have data on their effects over decades of use [1]. There are also open questions about the optimal balance of hormones in the triple agonists (e.g., the right ratio of glucagon to GLP-1 activity) and whether GIP should be activated or blocked for the best results [6]. Finally, the long-term effects on the cardiovascular system from sustained GIP receptor activation are not fully understood, and there is potential for pharmacogenomic variability — meaning the drugs may work differently in different people based on their genes [2][5].
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2023 to 2026, 9 from 2024 or later, 4 in Q1 journals, collectively cited 192 times — selected as the most relevant from 12 studies that passed quality screening, drawn from 35 papers retrieved from a database of over 500 million.
Sources used in this answer
The Incretin Revolution: Transforming Metabolic Medicine Review Article
GLP-1 RAs consistently lower HbA1c by 1-2%, reduce body weight by 5-22%, and decrease major cardiovascular event risk by 9-20%; newer poly-agonists like tirzepatide and retatrutide expand treatment options, but cost, tolerability, and long-term safety remain challenges.
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Dual GIP/GLP-1 agonist tirzepatide and triple agonist retatrutide have shown up to 24% body weight reduction and improvements in hepatic and inflammatory markers, but challenges persist in cost, accessibility, and underrepresentation of low- and middle-income countries in trials.
Incretins and the cardiovascular system: bridging digestion with metabolism
Incretin hormones (GLP-1 and GIP) link digestion, metabolism, and cardiovascular function by promoting vasodilation, improving endothelial function, and reducing cardiac workload; GLP-1 RAs and dual agonists leverage these effects to improve cardiovascular and possibly renal outcomes.
Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders
Dual and triple incretin-based therapies targeting GLP-1, GIP, and glucagon receptors enhance glycemic control, reduce body weight, and improve liver outcomes, with tirzepatide and retatrutide showing unprecedented efficacy, though safety, accessibility, and long-term use remain concerns.
The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to selective GLP-1 RAs in clinical trials, demonstrating synergistic actions between the two incretin pathways.
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
GLP-1 RAs and newer combinations with glucagon and/or GIP agonists have shown improvements in weight, insulin resistance, and non-invasive liver parameters in MASH patients, but the optimal ratio of agonists and whether GIP agonism or antagonism is best remains uncertain.
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Multi-incretin receptor agonists, including GIPR:GLP-1R:GCGR triagonists, rival the efficacy of bariatric surgery in preclinical models and clinical trials, but further research is needed on their mechanisms and how to achieve sustained weight loss without adverse effects.
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.
Single, dual, or triple incretin receptor agonists are becoming a promising treatment option for MASLD/MASH, with phase 2 trials showing histological improvements and benefits on extrahepatic complications, especially in patients with coexisting obesity or type 2 diabetes.
Incretin integration: Charting the future of cardiovascular-kidney-metabolic health
Incretin-based therapies, particularly GLP-1 RAs and GIP/GLP-1 RA dual agonists, are now cornerstones of cardiovascular-kidney-metabolic health, demonstrating significant cardiovascular and renal benefits beyond glycemic control.
Sleep and Circadian Effects on the Incretin System
GLP-1 secretion exhibits a circadian rhythm disrupted by high-fat diet and meal timing; insufficient sleep alters postprandial GLP-1 release, and the FDA has approved tirzepatide for treating obstructive sleep apnea.